Expert Opin Pharmacother. 15 (14): 2071–9. doi:10.1517/14656566.2014.949237. PMID 25186109. S2CID 25338932. Heinemann LA, Dinger J (2004). "Safety of a new oral contraceptive containing drospirenone". Drug Saf. 27 (13): 1001–18. doi:10.2165/00002018-200427130-00003. PMID 15471507. S2CID 1773936. Idota N, Kobayashi M, Miyamori D, Kakiuchi Y, Ikegaya H (March 2015). "Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature". Leg Med (Tokyo). 17 (2): 109–15. doi:10.1016/j.legalmed.2014.10.001. PMID 25454533. Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treat Endocrinol. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694. Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226. Larivée N, Suissa S, Khosrow-Khavar F, Tagalakis V, Filion KB (September 2017). "Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies". BJOG. 124 (10): 1490–1499. doi:10.1111/1471-0528.14623. PMID 28276140. Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A (2015). "Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review". Eur J Contracept Reprod Health Care. 20 (5): 329–43. doi:10.3109/13625187.2015.1050091. PMID 26007631. S2CID 41601833. Li J, Ren J, Sun W (March 2017). "A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome". Eur. J. Obstet. Gynecol. Reprod. Biol. 210: 13–21. doi:10.1016/j.ejogrb.2016.11.013. PMID 27923166. Lopez LM, Kaptein AA, Helmerhorst FM (February 2012). "Oral contraceptives containing drospirenone for premenstrual syndrome".
The device delivers a subcutaneous injection of sumatriptan, without the use of a needle. Autoinjectors with needles have been previously available in Europe and North America.Phase III studies with an iontophoretic transdermal patch (Zelrix/Zecuity) started in July 2008. This patch uses low voltage controlled by a pre-programmed microchip to deliver a single dose of sumatriptan through the skin within 30 minutes. Zecuity was approved by the US FDA in January 2013. Sales of Zecuity have been stopped following reports of skin burns and irritation. Society and culture
Legal status
In the United States, it is available only by medical prescription. This requirement for a medical prescription also exists in Australia. However, it can be bought over the counter in the UK and Sweden.In Russia versions of sumatriptan, which are not registered in the National registry of medications, may be regarded as narcotic drugs (derivatives of dimethyltriptamine). Generics
Glaxo patents for sumatriptan expired in February 2009. At that time, Imitrex sold for about $25 a pill. Par Pharmaceutical then introduced generic versions of sumatriptan injection (sumatriptan succinate injection) 4- and 6-mg starter kits and 4- and 6-mg filled syringe cartridges, and 6-mg vials soon after.Mylan Laboratories Inc., Ranbaxy Laboratories, Sandoz (a subsidiary of Novartis), Dr. Reddys Laboratories, and other companies have been producing generic versions of sumatriptan tablets in 25-, 50-, and 100-mg doses. Generic forms of the drug are available in U.S. and European markets after Glaxos patent protections expired in the respective countries.